^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Erivedge (vismodegib)

    i
    Other names: GDC 0449, GDC-0449, GDC0449, R 3616, R3616, RG3616, RG 3616, RO5450815, RO-5450815, RO 5450815, R-3616, RG-3616
    Company:
    Curis, Roche
    Drug class:
    Hedgehog cell-signalling pathway inhibitor
    Related drugs:
    6d
    A Large Basal Cell Carcinoma Treated With Hedgehog Inhibitor: A Case Report. (PubMed, Cureus)
    Sonidegib and vismodegib are synthetic mimetics of hedgehog pathway inhibitors that are indicated for many subtypes of advanced BCC. After eight months of hedgehog pathway inhibitor (HHI) therapy, the patient reported dramatic improvements in his BCC and complete regression of smaller BCCs previously noted on his upper extremities. The patient reported only minor adverse events including hair thinning, weight loss, and rapidly growing nails.
    Journal
    |
    PTCH1 (Patched 1)
    |
    Erivedge (vismodegib) • Odomzo (sonidegib)
    26d
    A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma (clinicaltrials.gov)
    P2, N=660, Active, not recruiting, St. Jude Children's Research Hospital | Trial primary completion date: Sep 2024 --> Sep 2025
    Trial primary completion date
    |
    cisplatin • gemcitabine • cyclophosphamide • pemetrexed • vincristine • Erivedge (vismodegib)
    1m
    Molecular characterization of adult non-glioblastoma central nervous system (CNS) tumors to identify potential targettable alterations (AIOM 2024)
    4 pts received TT at recurrence, within clinical trials: one with grade 3 meningioma and ALK rearrangement treated with alectinib, one with PTCH1 mutant medulloblastoma treated with vismodegib, and two with high TMB treated with nivolumab/ipilumumab. The incidence of targettable molecular alterations in adult CNS tumor patients was lower than in GBM. Nevertheless, in a few selected cases TT have the potential to increase treatment options at recurrence and improve outcomes.
    Clinical • Tumor mutational burden • BRCA Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • MET (MET proto-oncogene, receptor tyrosine kinase) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • FGFR1 (Fibroblast growth factor receptor 1) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • NF1 (Neurofibromin 1) • POLE (DNA Polymerase Epsilon) • MDM2 (E3 ubiquitin protein ligase) • PTCH1 (Patched 1) • NF2 (Neurofibromin 2) • BRCA (Breast cancer early onset) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF V600E • BRCA2 mutation • BRCA1 mutation • TMB-H • PIK3CA mutation • MET amplification • ALK rearrangement • FGFR1 amplification • POLE mutation • NF1 mutation • MDM2 amplification • RET mutation • PTCH1 mutation • NF2 mutation • ROS1 mutation • BRCA mutation • ALK rearrangement + PIK3CA mutation • PTCH1 rearrangement • NTRK fusion
    |
    FoundationOne® CDx
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Alecensa (alectinib) • Erivedge (vismodegib)
    1m
    Computer-Aided Identification and Design of Ligands for Multi-Targeting Inhibition of a Molecular Acute Myeloid Leukemia Network. (PubMed, Cancers (Basel))
    Overall, by integrating network and structural pharmacology with molecular modeling, we determined two complementary strategies with the potential to annihilate the AML network, one in the form of repurposable drug combinations and the other as a de novo synthesized triple-targeting agent. These target-drug interactions could be prioritized for preclinical and clinical testing toward precision medicine for AML.
    Journal
    |
    DNMT3A (DNA methyltransferase 1)
    |
    Iclusig (ponatinib) • Erivedge (vismodegib) • Tavalisse (fostamatinib)
    3ms
    Identification of Disulfidptosis-Related LncRNA Subtypes, Establishment of a Prognostic Signature, and Characterization of Immune Infiltration in Ovarian Cancer. (PubMed, Comb Chem High Throughput Screen)
    Our disulfidptosis-related lncRNA signature comprised of AL157871.2, HCP5, AC027348.1, AL109615.3, AL928654.1, LINC02585, and AC011445.1 could serve as a prognostic biomarker and guidance to therapy response for OC patients.
    Journal • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    Lynparza (olaparib) • imatinib • Tasigna (nilotinib) • Erivedge (vismodegib)
    3ms
    Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, Dwight Owen
    New P1 trial • Metastases
    |
    Tecentriq (atezolizumab) • Erivedge (vismodegib)
    3ms
    Inherited Basaloid Neoplasms Associated With SUFU Pathogenic Variants. (PubMed, JAMA Dermatol)
    Awareness of the clinicopathologic spectrum of SUFU-associated basaloid neoplasms is important for dermatologists and dermatopathologists because many (although not all) of these lesions are indolent and do not require aggressive surgical treatment. Importantly, because SUFU lies downstream of the protein smoothened, vismodegib and other smoothened inhibitors are unlikely to be effective therapies in this subset of patients.
    Journal
    |
    PTCH1 (Patched 1)
    |
    Erivedge (vismodegib)
    3ms
    A071401: Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients with Progressive Meningiomas (clinicaltrials.gov)
    P2, N=124, Recruiting, Alliance for Clinical Trials in Oncology | Trial completion date: Oct 2024 --> Jan 2028 | Trial primary completion date: Oct 2024 --> Jan 2026
    Trial completion date • Trial primary completion date
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • CCND1 (Cyclin D1) • CCNE1 (Cyclin E1) • PTCH1 (Patched 1) • CDK4 (Cyclin-dependent kinase 4) • NF2 (Neurofibromin 2) • SMO (Smoothened Frizzled Class Receptor) • CDK6 (Cyclin-dependent kinase 6) • CCND2 (Cyclin D2) • CCND3 (Cyclin D3)
    |
    PIK3CA mutation • PTEN mutation • CDKN2A mutation • PTCH1 mutation • NF2 mutation • AKT1 mutation • SMO mutation • PIK3CA mutation + PTEN mutation • CDK4 mutation
    |
    Verzenio (abemaciclib) • Truqap (capivasertib) • Erivedge (vismodegib) • GSK2256098
    4ms
    Images in Immunotherapy and Precision Oncology: Advanced Basal Cell Carcinoma. (PubMed, J Immunother Precis Oncol)
    However, targeted therapies such as sonidegib and vismodegib - sonic hedgehog pathway inhibitors - have emerged that have been approved for treating BCC, as have anti-PD1 immunotherapies, such as cemiplimab, with their success likely based on the high tumor mutational burden seen in some of these tumors. Epidermal growth factor receptor (EGFR) inhibitors also serve a role in treating this condition as well. Molecular studies on metastatic/advanced BCC and other rare malignancies may inform treatment therapeutic decisions.
    Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    TMB (Tumor Mutational Burden)
    |
    Libtayo (cemiplimab-rwlc) • Erivedge (vismodegib) • Odomzo (sonidegib)
    5ms
    Surgical Debulking Modifies Notch Signaling and May Improve Vismodegib Effectiveness for Locally Advanced Basal Cell Carcinoma. (PubMed, JID Innov)
    Patients 1, 3, and 4 displayed a clinical response to debulking followed by vismodegib, whereas patient 2 was lost to follow-up after debulking. These findings suggest that surgical manipulation of LaBCCs is correlated with molecular alterations in signaling pathways associated with cellular reprogramming.
    Journal • Metastases
    |
    RUNX1 (RUNX Family Transcription Factor 1) • PTCH1 (Patched 1) • ALCAM (Activated Leukocyte Cell Adhesion Molecule) • FZD2 (Frizzled Class Receptor 2)
    |
    Erivedge (vismodegib)
    5ms
    Bioactive nanocomposite hydrogel enhances postoperative immunotherapy and bone reconstruction for osteosarcoma treatment. (PubMed, Biomaterials)
    Here, we developed a nanocomposite hydrogel for the sustained co-delivery of bioactive magnesium ions, anti-PD-L1 antibody (αPD-L1), and hedgehog pathway antagonist vismodegib, to eradicate residual tumor cells while promoting bone regeneration post-surgery...After 21 days, the expression levels of ALP, COL1, RUNX2, and BGLAP in the Vis-αPD-L1-Gel group were approximately 4.1, 5.1, 5.5, and 3.4 times higher than those of the control, respectively. We believe that this hydrogel-based combination therapy offers a potentially valuable strategy for treating osteosarcoma and addressing the tumor-related complex bone diseases.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • RUNX2 (RUNX Family Transcription Factor 2) • BGLAP (Bone Gamma-Carboxyglutamate Protein)
    |
    Erivedge (vismodegib)
    5ms
    Combination of Vismodegib and Paclitaxel Enhances Cytotoxicity via Bak-mediated Mitochondrial Damage in EGFR-Mutant Non-Small Cell Lung Cancer Cells. (PubMed, Cell Biochem Biophys)
    However, Vis enhanced PTX-induced Bak activation, leading to mitochondrial damage, ROS accumulation, and subsequent apoptosis. Our findings suggest that the combination of Vis and PTX could be a potential therapeutic strategy to increase PTX sensitivity of EGFR-mutant NSCLC.
    Journal • PARP Biomarker
    |
    EGFR (Epidermal growth factor receptor) • CASP3 (Caspase 3) • ANXA5 (Annexin A5)
    |
    paclitaxel • Erivedge (vismodegib)
    5ms
    Molecular characterization of adult non-glioblastoma central nervous system (CNS) tumors to identify potential targettable alterations (ESMO 2024)
    4 pts received TT at recurrence, within clinical trials: one with grade 3 meningioma and ALK rearrangement treated with alectinib, one with PTCH1 mutant medulloblastoma treated with vismodegib, and two with high TMB treated with nivolumab/ipilumumab. The incidence of targettable molecular alterations in adult CNS tumor pts was lower than in GBM. Nevertheless, in a few selected cases TT have the potential to increase treatment options at recurrence and improve outcomes.
    Clinical • Tumor mutational burden • PD(L)-1 Biomarker • BRCA Biomarker • IO biomarker
    |
    BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • MET (MET proto-oncogene, receptor tyrosine kinase) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • FGFR1 (Fibroblast growth factor receptor 1) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • NF1 (Neurofibromin 1) • MDM2 (E3 ubiquitin protein ligase) • PTCH1 (Patched 1) • BRCA (Breast cancer early onset) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF V600E • TMB-H • MET amplification • ALK rearrangement • FGFR1 amplification • MDM2 amplification • PTCH1 mutation • BRCA mutation • FGFR3 amplification • PTCH1 rearrangement • NTRK fusion
    |
    FoundationOne® CDx
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Alecensa (alectinib) • Erivedge (vismodegib)
    5ms
    Hedgehog Pathway and Programmed Cell Death Protein-1 Inhibitors for Advanced Basal Cell Carcinoma. (PubMed, Case Rep Dermatol)
    Here we report in detail the management of three complex advanced BCC (aBCC) after treatment failure with vismodegib...However, despite the high tumor mutational burden of aBCCs, immunotherapy does not always lead to a long response. Rechallenge or combining treatment of hedgehog inhibitors and PD-1 inhibitors by parallel or alternating cycles may be a strategy to lengthen the treatment response.
    Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    TMB (Tumor Mutational Burden)
    |
    Erivedge (vismodegib)
    5ms
    Cancer Molecular Screening and Therapeutics (MoST) Program Substudy Addendum 4 substudy 9: vismodegib (ACTRN12618000281291)
    P2, N=16, Completed, The University of Sydney | Active, not recruiting --> Completed
    Trial completion
    |
    PTCH1 (Patched 1) • SMO (Smoothened Frizzled Class Receptor)
    |
    Erivedge (vismodegib)
    6ms
    SHH induces macrophage oxidative phosphorylation and efferocytosis to promote scar formation. (PubMed, Cell Commun Signal)
    Notably, targeting SHH signaling with vismodegib exhibited promising potential in mitigating scar formation by reversing the effects of enhanced OXPHOS and M2 polarization in macrophages. In conclusion, this study underscores the critical roles of macrophage metabolism, particularly OXPHOS, efferocytosis and SHH signaling in cutaneous scar formation. Understanding these mechanisms provides new avenues for potential interventions and scar prevention strategies.
    Journal
    |
    SHH (Sonic Hedgehog Signaling Molecule)
    |
    Erivedge (vismodegib)
    6ms
    CUPISCO: A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site (clinicaltrials.gov)
    P2, N=528, Active, not recruiting, Hoffmann-La Roche | N=790 --> 528
    Enrollment change
    |
    Avastin (bevacizumab) • Lynparza (olaparib) • cisplatin • Tecentriq (atezolizumab) • erlotinib • Zelboraf (vemurafenib) • carboplatin • gemcitabine • Rozlytrek (entrectinib) • paclitaxel • Alecensa (alectinib) • Perjeta (pertuzumab) • Cotellic (cobimetinib) • Pemazyre (pemigatinib) • Tibsovo (ivosidenib) • ipatasertib (RG7440) • Erivedge (vismodegib) • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk)
    7ms
    Structural basis for the bi-specificity of USP25 and USP28 inhibitors. (PubMed, EMBO Rep)
    To obtain insights into their mode of inhibition, we structurally and functionally characterized USP28 in the presence of the three different inhibitors AZ1, Vismodegib and FT206...Furthermore, a key glutamate residue at position 366/373 in USP28/USP25 plays a central structural role for pocket stability and thereby for inhibition and activity. Obstructing the inhibitor-binding pocket by mutation of this glutamate may provide a tool to accelerate future drug development efforts for selective inhibitors of either USP28 or USP25 targeting distinct binding pockets.
    Journal
    |
    USP25 (Ubiquitin Specific Peptidase 25)
    |
    Erivedge (vismodegib)
    7ms
    Alopecia due to chemotherapeutics, hedgehog inhibitors, targeted antibody therapies and immune checkpoint inhibitors : Pathogenesis, clinical picture, diagnostics and prophylaxis (PubMed, Dermatologie (Heidelb))
    Chemotherapy-induced hair loss (CIA) occurs in up to 65% of cases. Anagen effluvium is observed as early as 1-3 weeks after the start of treatment and is reversible in most cases. Alopecia associated with inhibitors of the Sonic Hedgehog signaling pathway (HHIA) such as vismodegib or sonidegib are observed in up to 60% of cases. They are characterized by telogen effluvium. BRAF or immune checkpoint inhibitors lead significantly less frequently to alopecia (BRAFA, CPIA). According to taxane-based chemotherapy protocols, scalp cooling can help to prevent higher-grade CIA. If CIA or other forms of alopecia are expected, early contact with self-help organizations and early prescriptions for wigs should be offered.
    Review • Journal • Checkpoint inhibition
    |
    BRAF (B-raf proto-oncogene)
    |
    Erivedge (vismodegib) • Odomzo (sonidegib)
    7ms
    Vismodegib Potentiates Marine Antimicrobial Peptide Tilapia Piscidin 4-Induced Cytotoxicity in Human Non-Small Cell Lung Cancer Cells. (PubMed, Probiotics Antimicrob Proteins)
    Thus, we conclude that hedgehog regulates the cytotoxic sensitivity of NSCLC cells to TP4 by protecting against mitochondrial dysfunction and suppressing oxidative stress. These findings suggest that combined treatment of vismodegib and TP4 may be a promising therapeutic strategy for NSCLC.
    Journal • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • BCL2 (B-cell CLL/lymphoma 2) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • CAT (Catalase)
    |
    EGFR mutation
    |
    Erivedge (vismodegib)
    8ms
    A novel TCGA-validated programmed cell-death-related signature of ovarian cancer. (PubMed, BMC Cancer)
    Our model could precisely predict the prognosis, immune status and drug sensitivity of OC patients.
    Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • RB1 (RB Transcriptional Corepressor 1) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • IDO1 (Indoleamine 2,3-dioxygenase 1) • CLTC (Clathrin Heavy Chain) • IGF2BP1 (Insulin Like Growth Factor 2 MRNA Binding Protein 1) • OGG1 (8-Oxoguanine DNA glycosylase) • PPP1R15A (Protein Phosphatase 1 Regulatory Subunit 15A) • UBR5 (Ubiquitin Protein Ligase E3 Component N-Recognin 5) • CD3E (CD3 Epsilon Subunit Of T-Cell Receptor Complex)
    |
    cisplatin • gefitinib • paclitaxel • Erivedge (vismodegib)
    9ms
    Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T) (clinicaltrials.gov)
    P2, N=35, Active, not recruiting, National Cancer Institute (NCI)
    New P2 trial
    |
    Erivedge (vismodegib)
    9ms
    To Assess the Safety and Efficacy of SP-002 With Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma (clinicaltrials.gov)
    P2, N=80, Recruiting, Stamford Pharmaceuticals, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    Erivedge (vismodegib)
    9ms
    To Assess the Safety and Efficacy of SP-002 With Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, Stamford Pharmaceuticals, Inc.
    New P2 trial
    |
    Erivedge (vismodegib)
    10ms
    GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery (clinicaltrials.gov)
    P1, N=55, Active, not recruiting, National Cancer Institute (NCI)
    Trial completion date • Surgery • Metastases
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    erlotinib • gemcitabine • Erivedge (vismodegib)
    10ms
    A sterol analog inhibits hedgehog pathway by blocking cholesterylation of smoothened. (PubMed, Cell Chem Biol)
    Q29 exhibits an additive inhibitory effect on medulloblastoma with vismodegib, a clinically used SMO-7TM inhibitor for treating basal cell carcinoma (BCC). Importantly, Q29 overcomes resistance caused by SMO mutants against SMO-7TM inhibitors and inhibits the activity of SMO oncogenic variants. Our work demonstrates that the SMO-CRD inhibitor can be a new way to treat Hh pathway-driven cancers.
    Journal
    |
    SMO (Smoothened Frizzled Class Receptor)
    |
    SMO mutation
    |
    Erivedge (vismodegib)
    10ms
    Plasma ctDNA Monitoring of a PTCH1-Mutant Metastatic Adult Medulloblastoma Showing a Durable Benefit With Vismodegib. (PubMed, Oncologist)
    Several small studies demonstrate objective but short-lived responses to SMO inhibitors such as vismodegib or sonidegib. We present the case of a 26-year-old patient with a recurrent MB, in which next-generation sequencing (FoundationOne CDx) revealed a mutation in PTCH1, allowing the patient to be treated with vismodegib in second line, resulting in a durable benefit lasting for 1 year. Using an in-house digital PCR probe, the PTCH1 mutation could be tracked in ctDNA during treatment with first-line chemotherapy and while on treatment with vismodegib, demonstrating a precise correlation with the radiological and clinical behavior of the disease.
    Journal • Circulating tumor DNA • Metastases
    |
    TP53 (Tumor protein P53) • TERT (Telomerase Reverse Transcriptase) • PTCH1 (Patched 1) • SMO (Smoothened Frizzled Class Receptor)
    |
    TP53 wild-type • PTCH1 mutation • SMO mutation
    |
    FoundationOne® CDx
    |
    Erivedge (vismodegib) • Odomzo (sonidegib)
    10ms
    Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial (clinicaltrials.gov)
    P1, N=2, Terminated, OHSU Knight Cancer Institute | Active, not recruiting --> Terminated; Low accrual
    Trial termination
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Venclexta (venetoclax) • Lynparza (olaparib) • Mekinist (trametinib) • erlotinib • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Zelboraf (vemurafenib) • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • sorafenib • Rozlytrek (entrectinib) • imatinib • sunitinib • everolimus • Nerlynx (neratinib) • Iclusig (ponatinib) • Kadcyla (ado-trastuzumab emtansine) • Cotellic (cobimetinib) • Lorbrena (lorlatinib) • Lenvima (lenvatinib) • bortezomib • doxorubicin hydrochloride • capecitabine • Verzenio (abemaciclib) • Xtandi (enzalutamide) • Cabometyx (cabozantinib tablet) • albumin-bound paclitaxel • Stivarga (regorafenib) • abiraterone acetate • oxaliplatin • Aliqopa (copanlisib) • Vizimpro (dacomitinib) • Zydelig (idelalisib) • daunorubicin • Zolinza (vorinostat) • Idhifa (enasidenib) • Farydak (panobinostat) • Erivedge (vismodegib) • Nubeqa (darolutamide) • bicalutamide • leucovorin calcium • cabazitaxel • Vesanoid (tretinoin) • fluorouracil topical
    10ms
    Beyond cyclopamine: Targeting Hedgehog signaling for cancer intervention. (PubMed, Arch Biochem Biophys)
    Inhibiting Hh signaling is an important oncological strategy in which inhibitors of the ligands SMO or GLI have been looked at. This review briefly narrates the Hh ligands, signal transduction, the target genes involved and comprehensively describes the numerous inhibitors that have been evaluated for use in various neoplastic settings.
    Review • Journal
    |
    GLI1 (GLI Family Zinc Finger 1)
    |
    Erivedge (vismodegib) • Odomzo (sonidegib) • cyclopamine
    10ms
    IMPRESS-Norway: Improving Public Cancer Care by Implementing Precision Medicine in Norway (clinicaltrials.gov)
    P2, N=3000, Recruiting, Oslo University Hospital | N=1000 --> 3000
    Enrollment change
    |
    Avastin (bevacizumab) • Herceptin (trastuzumab) • Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • Rozlytrek (entrectinib) • Alecensa (alectinib) • Perjeta (pertuzumab) • Zejula (niraparib) • Zykadia (ceritinib) • Jemperli (dostarlimab-gxly) • Erivedge (vismodegib) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)
    10ms
    My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P2, N=673, Completed, Genentech, Inc. | Phase classification: P2a --> P2
    Phase classification
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden) • PTCH1 (Patched 1) • SMO (Smoothened Frizzled Class Receptor)
    |
    EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • BRAF V600 • ALK rearrangement • ALK mutation • SMO mutation
    |
    Herceptin (trastuzumab) • Tecentriq (atezolizumab) • erlotinib • Zelboraf (vemurafenib) • Alecensa (alectinib) • Perjeta (pertuzumab) • Cotellic (cobimetinib) • Erivedge (vismodegib)
    11ms
    Ablative fractional laser treatment reduces hedgehog pathway gene expression in murine basal cell carcinomas. (PubMed, Lasers Med Sci)
    In conclusion, a single AFL treatment significantly reduced hedgehog gene expression in murine BCCs mimicking the effects of eight topical applications of vismodegib. Further studies are needed to assess whether AFL can be utilized for BCC treatment, either as monotherapy or in combination with other drugs.
    Preclinical • Journal
    |
    PTCH1 (Patched 1) • GLI1 (GLI Family Zinc Finger 1) • GLI2 (GLI Family Zinc Finger 2)
    |
    GLI1 expression
    |
    Erivedge (vismodegib)
    11ms
    Laser-assisted topical delivery of vismodegib reduces hedgehog gene expression in human basal cell carcinomas in vivo. (PubMed, Lasers Surg Med)
    A single AFL-assisted topical application of vismodegib resulted in clinically relevant intratumoral drug concentrations and significant reductions in hedgehog pathway gene expressions.
    Preclinical • Journal
    |
    PTCH1 (Patched 1) • GLI1 (GLI Family Zinc Finger 1) • GLI2 (GLI Family Zinc Finger 2)
    |
    GLI1 expression
    |
    Erivedge (vismodegib) • Odomzo (sonidegib)
    11ms
    Photobiomodulation Recovers the Submandibular Gland in Vismodegib-Treated Rats. (PubMed, Photobiomodul Photomed Laser Surg)
    Also, 850 nm high-power LED recovered the damaged structure of SMG and increased SHH-related proteins and salivary functional markers. The study results suggest that PBM can restore SMG structure and function through SHH signaling.
    Preclinical • Journal
    |
    PTCH1 (Patched 1) • GLI1 (GLI Family Zinc Finger 1) • KRT5 (Keratin 5) • SHH (Sonic Hedgehog Signaling Molecule)
    |
    Erivedge (vismodegib)
    11ms
    Dynamic optical coherence tomography evaluation in locally advanced basal cell carcinoma during sonidegib treatment. (PubMed, J Eur Acad Dermatol Venereol)
    Sonidegib can be considered an effective treatment option in cases where surgery or radiotherapy would be unfeasible or has previously failed, although pigmented lesions did not show complete clearance, suggesting that there are factors other than the SHH pathway involved in tumour growth. Videodermoscopy and D-OCT were useful in the quick and seamless follow-up of lesions and added valuable information in assessing efficacy.
    Journal • Metastases
    |
    PTCH1 (Patched 1) • SMO (Smoothened Frizzled Class Receptor)
    |
    PTCH1 mutation • SMO mutation
    |
    Erivedge (vismodegib) • Odomzo (sonidegib)
    11ms
    SMMART Adaptive Clinical Treatment (ACT) Trial (clinicaltrials.gov)
    P1, N=0, Withdrawn, OHSU Knight Cancer Institute | N=25 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation • HR positive • HER-2 negative • EGFR positive
    |
    Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • carboplatin • Rozlytrek (entrectinib) • Alecensa (alectinib) • Kadcyla (ado-trastuzumab emtansine) • Cotellic (cobimetinib) • capecitabine • Piqray (alpelisib) • Zejula (niraparib) • albumin-bound paclitaxel • fulvestrant • irinotecan • Halaven (eribulin mesylate) • letrozole • vinorelbine tartrate • Herzuma (trastuzumab-pkrb) • anastrozole • Erivedge (vismodegib) • Trazimera (trastuzumab-qyyp) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)
    11ms
    A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma (clinicaltrials.gov)
    P2, N=660, Active, not recruiting, St. Jude Children's Research Hospital | Trial primary completion date: Jan 2025 --> Sep 2024
    Trial primary completion date
    |
    cisplatin • gemcitabine • cyclophosphamide • pemetrexed • vincristine • Erivedge (vismodegib)
    1year
    The HEDGEHOG-GLI1 pathway is important for fibroproliferative properties in keloids and as a candidate therapeutic target. (PubMed, Commun Biol)
    Moreover, the HH signal inhibitor vismodegib reduced keloid reconstituted tumor size and keloid-related gene expression in nude mice and the collagen bundle and expression of cytokines characteristic for keloids in ex vivo culture of keloid tissues. These results implicate the HH-GLI1 pathway in keloid pathogenesis and suggest therapeutic targets of keloids.
    Journal
    |
    SPP1 (Secreted Phosphoprotein 1) • GLI1 (GLI Family Zinc Finger 1)
    |
    Erivedge (vismodegib)
    1year
    The Sonic hedgehog pathway inhibitor GDC0449 induces autophagic death in human Medulloblastoma Daoy cells. (PubMed, Ultrastruct Pathol)
    It was observed that inhibiting autophagy using Beclin1 siRNA significantly blocked the apoptosis-inducing effects of GDC0449, suggesting that GDC0449 mediates its apoptotic effects by inducing autophagy.Our data suggests that GDC0449 inhibits the growth of human MB Daoy cells by autophagy-mediated apoptosis. The mechanism of GDC0449-induced autophagy in Daoy cells may be related to the inhibition of the PI3K/AKT/mTOR signaling pathway.
    Journal
    |
    CASP3 (Caspase 3) • EIF4EBP1 (Eukaryotic translation initiation factor 4E binding protein 1) • BECN1 (Beclin 1)
    |
    Erivedge (vismodegib)
    1year
    Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (clinicaltrials.gov)
    P2, N=48, Recruiting, Ronald Buckanovich | Trial completion date: Mar 2026 --> Apr 2028 | Trial primary completion date: Mar 2025 --> Apr 2028
    Trial completion date • Trial primary completion date
    |
    BRCA (Breast cancer early onset) • CD4 (CD4 Molecule)
    |
    Tecentriq (atezolizumab) • Erivedge (vismodegib)
    1year
    Signaling Pathways and Therapeutic Strategies in Advanced Basal Cell Carcinoma. (PubMed, Cells)
    The discovery of mutations in the Hh signaling pathway has paved the way for the development of Hh pathway inhibiting agents, such as vismodegib and sonidegib, which have represented a breakthrough in the aBCC management. However, the use of these agents is limited by the frequent occurrence of adverse events or the development of drug resistance. In this review, we thoroughly describe the current knowledge regarding the available options for the pharmacological management of aBCCs and provide a forward-looking update on novel therapeutic strategies that could enrich the therapeutic armamentarium of BCC in the near future.
    Review • Journal • Metastases
    |
    SMO (Smoothened Frizzled Class Receptor)
    |
    Erivedge (vismodegib) • Odomzo (sonidegib)
    1year
    Turning enemy into ally: hijack brain tumor cells to break down the blood-tumor barrier (SNO 2023)
    Using a genetically engineered mouse model of SHH MB, we show that tumor-specific knockout of volume-regulated ion channel, Lrrc8a, significantly increases BTB permeability and enhances the therapeutic response of MB-bearing mice to vismodegib, an FDA-approved antagonist of the SHH pathway...Furthermore, tumor-specific LRRC8A knockdown enhances BTB permeability in a xenograft human Group 3 MB model. Collectively, our findings establish Lrrc8a/LRRC8A as a therapeutic target to increase the therapy response of MB and provide evidence that inducing EndMT could be a strategy for enhancing BTB permeability to treat brain cancer.
    Tumor cell
    |
    LRRC8A (Leucine Rich Repeat Containing 8 VRAC Subunit A) • TGFB2 (Transforming Growth Factor Beta 2)
    |
    Erivedge (vismodegib)